BDP-8900 MRCK Small Molecule Inhibitor

MRCK contributes to tumour cell invasiveness and may be an important driver of metastasis.BDP-8900 is a potent MRCK inhibitor.

Contributors

Institute
Cancer Research UK, Glasgow: The Beatson Institute
Cat. #: 160843
Tool sub type: Inhibitor
Research Fields: Cancer
Application: Protein crystallization, Cell line screening,
Purpose: Inhibitor
Alternate name: myotonic dystrophy kinase-related CDC42-binding kinase, MRCK
Product description: Members of the RhoGTPase family are central regulators of the actin-myosin cytoskeleton and have been shown to contribute to multiple processes associated with invasion and metastasis. Cdc42 signals through effector proteins including the myotonic dystrophy kinase-related Cdc42-binding kinases a and β (MRCKβ and MRCKβ), which are 190 kDa multi-domain proteins with ~80% amino acid identity across their kinase domains, that are expressed in a wide range of tissues. MRCK and the Rho-regulated ROCK kinases belong to the AGC kinase family, and share ~45-50% amino acid identity in their N-terminal kinase domains, which is reflected in their shared abilities to phosphorylate a similar set of substrates including MLC and the inhibitory phosphorylation of the myosin binding subunit (MYPT1) of the MLC phosphatase complex. However, MRCK and ROCK kinases may phosphorylate substrates, such as MLC, at different subcellular localizations due to their specific interactions with targeting proteins and/or lipids. Importantly, it has been observed that the actin-myosin contractility required for the invasion of three-dimensional extracellular protein matrices by MDA-MB-231 breast cancer cells, and for the collective invasion of squamous cell carcinoma (SCC) cells through three dimensional collagen matrices in an organotypic model were dependent on MRCK signalling. Elevated MRCKβ expression was reported to contribute to Ras oncogene-driven SCC development in genetically-modified mice following repression of the Notch 1 tumour suppressor. In addition, gene expression analysis identified MRCKβ as part of a breast cancer gene expression signature linked to poor patient prognosis and increased incidence of metastasis under five years. These observations indicate that MRCK contributes to tumour cell invasiveness and may be an important driver of metastasis. BDP-8900 is a potent MRCK inhibitor.
Molecular weight: 353.488
Chemical name: C19H23N5S
Selectivity: similar activity against MRCKι and MRCKβ; >562-fold selectivity over related ROCK1 or ROCK2 at MRCKβ in inhibition of myosin light-chain phosphorylation (pMLC2) in MDA-MB-231 human breast cancer cells, engineered to express tetracycline-inducible MRCKβ, ROCK1, or ROCK2 kinase domains.
Primary target: Myotonic dystrophy kinase-related CDC42-binding kinase IC50 = 43nM (MRCKβ)
References:

Unbekandt et al. 2018. Cancer Res. 78(8):2096-2114. PMID: 29382705.

Related Tools for Small molecules

Cat. # Tool Name
151831 Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound) Key Info View Tool
151880 AKR1C3 inhibitor CRT0093964 Small Molecule (Tool Compound) Key Info View Tool
152788 Phosphatidylinositol-4-phosphate 5-kinase inhibitor PIP5K Small Molecule (Collaborative Toolkit) Key Info View Tool
153191 CDK inhibitor BS-194 Small Molecule (Tool Compound) Key Info View Tool
153255 Autotaxin Inhibitor (CRT0273750) Small Molecule (Collaborative Toolkit) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.